Item 7.01 Regulation FD Disclosure.

On January 8, 2021 the Company issued a press release announcing top-line results from its 755-102-HV Phase 1 clinical trial including that the results indicate that INM-755 cream was safe and well-tolerated on induced open epidermal wounds, caused no systemic or serious adverse effects, and there were no subject withdrawals due to adverse events. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:





Exhibit
No.       Description

99.1        News release, dated ______________




                                       1

© Edgar Online, source Glimpses